Catalyst Pharmaceuticals Competitors and Similar CompaniesClear all
Catalyst Pharmaceuticals's competitors and similar companies include Omeros, Alnylam, ANI Pharmaceuticals and Olainfarm.
 Catalyst Pharmaceuticals Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases. |  Omeros Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  ANI Pharmaceuticals ANI Pharmaceuticals develops, manufactures and markets top quality prescription pharmaceuticals, made in the U.S.A. |  Olainfarm Olainfarm manufactures and distributes chemical and pharmaceutical products primarily in Latvia. | |
Founding Date | Founding Date 2002 | Founding Date 1994 | Founding Date 2002 | Founding Date 1996 | Founding Date 1972 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Coral Gables, US HQ | Locations Seattle, US HQ | Locations Baudette, US HQ Oakville, CA Baudette, US | Locations Olaine, LV HQ | |
Employees | Employees 7649% increase | Employees 1968% decrease | Employees 1,32324% increase | Employees 33813% increase | Employees 2,191 |
Valuation ($) | Valuation ($) 2.6 b | Valuation ($) 248.6 m | Valuation ($) 36.5 b | Valuation ($) 1.2 b | Valuation ($) 150.2 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $491.7m (FY, 2024) | Revenue (est.) N/A | Revenue (est.) $2.2b (FY, 2024) | Revenue (est.) $614.4m (FY, 2024) | Revenue (est.) €122.2m (FY, 2020) |
Cost of goods | Cost of goods $68.8m (FY, 2024) | Cost of goods N/A | Cost of goods $306.5m (FY, 2024) | Cost of goods N/A | Cost of goods €44.5m (FY, 2020) |
Gross profit | Gross profit $422.9m (FY, 2024) | Gross profit N/A | Gross profit $1.9b (FY, 2024) | Gross profit N/A | Gross profit €80.1m (FY, 2020) |
Net income | Net income $163.9m (FY, 2024) | Net income ($156.8m) (FY, 2024) | Net income ($278.2m) (FY, 2024) | Net income ($18.5m) (FY, 2024) | Net income €9.5m (FY, 2020) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 354.8m | Total funding raised $ 1.5b | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Omeros
HQ
Seattle, US
Employees
196↓ 8% decrease
Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers.
View companyAlnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View companyANI Pharmaceuticals
HQ
Baudette, US
Employees
338↑ 13% increase
ANI Pharmaceuticals develops, manufactures and markets top quality prescription pharmaceuticals, made in the U.S.A.
View companyOlainfarm
HQ
Olaine, LV
Employees
2,191
Olainfarm manufactures and distributes chemical and pharmaceutical products primarily in Latvia.
View company